Skip to main
CANF

CANF Stock Forecast & Price Target

CANF Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Can-Fite Biofarma Ltd is a clinical-stage biopharmaceutical company focusing on developing therapeutics targeting cancer, liver diseases, and inflammatory conditions, with promising candidates in pivotal clinical trials. The company anticipates significant revenue growth, projecting risk-adjusted sales from Can-Fite products to rise from approximately $3 million in 2027 to around $126 million by 2031, with Namodenoson alone expected to contribute approximately $19.7 million in global sales by that year. Furthermore, the strong clinical results, including a complete response in a patient treated with Namodenoson, along with FDA and EMA agreement on the Phase 3 protocol for Piclidenoson, enhance the company's outlook and strengthen its market position.

Bears say

The financial outlook for Can Fite Biofarma Ltd is negatively impacted by several fundamental concerns, particularly regarding its product commercialization and regulatory approval processes. The company has projected a net loss of $10 million for 2025, continuing a trend indicated by a $4.9 million loss in the first half of 2025, which raises concerns about its financial health and ability to sustain operations without additional funding. Furthermore, anticipated dilution from adjustments in the stock model, along with competitive pressures and potential intellectual property challenges, could significantly hinder Can Fite's revenue generation and market penetration, leading to a downward revision of its future valuation.

CANF has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Can-Fite BioPharma Ltd. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Can-Fite BioPharma Ltd. (CANF) Forecast

Analysts have given CANF a Strong Buy based on their latest research and market trends.

According to 2 analysts, CANF has a Strong Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Can-Fite BioPharma Ltd. (CANF)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.